Lee Chiang-Wen, Chiang Yao-Chang, Yu Pei-An, Peng Kuo-Ti, Chi Miao-Ching, Lee Ming-Hsueh, Fang Mei-Ling, Lee Kuan-Han, Hsu Lee-Fen, Liu Ju-Fang
Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Puzi, Taiwan.
Department of Nursing, Chang Gung University of Science and Technology, Puzi, Taiwan.
Front Oncol. 2021 Oct 25;11:735277. doi: 10.3389/fonc.2021.735277. eCollection 2021.
Osteosarcoma, a common aggressive and malignant cancer, appears in the musculoskeletal system among young adults. The major cause of mortality in osteosarcoma was the recurrence of lung metastases. However, the molecular mechanisms of metastasis involved in osteosarcomas remain unclear. Recently, CXCL1 and CXCR2 have been crucial indicators for lung metastasis in osteosarcoma by paracrine releases, suggesting the involvement of directing neutrophils into tumor microenvironment. In this study, overexpression of CXCL1 has a positive correlation with the migratory and invasive activities in osteosarcoma cell lines. Furthermore, the signaling pathway, CXCR2/FAK/PI3K/Akt, is activated through CXCL1 by promoting vascular cell adhesion molecule 1 (VCAM-1) upregulation of nuclear factor-kappa B (NF-κB) expression and nuclear translocation. The animal model further demonstrated that CXCL1 serves as a critical promoter in osteosarcoma metastasis to the lung. The correlated expression of CXCL1 and VCAM-1 was observed in the immunohistochemistry staining from human osteosarcoma specimens. Our findings demonstrate the cascade mechanism regulating the network in lung metastasis osteosarcoma, therefore indicating that the CXCL1/CXCR2 pathway is a worthwhile candidate to further develop treatment schemas.
骨肉瘤是一种常见的侵袭性恶性肿瘤,多见于年轻成年人的肌肉骨骼系统。骨肉瘤患者死亡的主要原因是肺转移复发。然而,骨肉瘤转移的分子机制仍不清楚。最近,CXCL1和CXCR2通过旁分泌释放成为骨肉瘤肺转移的关键指标,提示其参与引导中性粒细胞进入肿瘤微环境。在本研究中,CXCL1的过表达与骨肉瘤细胞系的迁移和侵袭活性呈正相关。此外,信号通路CXCR2/FAK/PI3K/Akt通过促进血管细胞黏附分子1(VCAM-1)上调核因子-κB(NF-κB)的表达和核转位而被CXCL1激活。动物模型进一步证明,CXCL1是骨肉瘤肺转移的关键促进因子。在人骨肉瘤标本的免疫组织化学染色中观察到CXCL1和VCAM-1的相关表达。我们的研究结果揭示了骨肉瘤肺转移网络的级联调控机制,因此表明CXCL1/CXCR2通路是进一步制定治疗方案的一个有价值的候选靶点。